Growth Metrics

TriSalus Life Sciences (TLSI) Change in Receivables (2022 - 2026)

TriSalus Life Sciences has reported Change in Receivables over the past 5 years, most recently at -$1.3 million for Q1 2026.

  • For Q1 2026, Change in Receivables fell 452.73% year-over-year to -$1.3 million; the TTM value through Mar 2026 reached -$23000.0, down 101.69%, while the annual FY2025 figure was $1.6 million, 4.94% down from the prior year.
  • Change in Receivables for Q1 2026 was -$1.3 million at TriSalus Life Sciences, down from $1.6 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $1.6 million in Q4 2025 and troughed at -$1.3 million in Q1 2026.
  • A 5-year average of $236071.4 and a median of $363500.0 in 2024 define the central range for Change in Receivables.
  • Biggest five-year swings in Change in Receivables: surged 1965.71% in 2024 and later plummeted 452.73% in 2026.
  • Year by year, Change in Receivables stood at -$736000.0 in 2022, then soared by 168.21% to $502000.0 in 2023, then decreased by 28.09% to $361000.0 in 2024, then skyrocketed by 340.72% to $1.6 million in 2025, then crashed by 181.14% to -$1.3 million in 2026.
  • Business Quant data shows Change in Receivables for TLSI at -$1.3 million in Q1 2026, $1.6 million in Q4 2025, and -$497000.0 in Q3 2025.